Search Results - "Weberpals, J I"

Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins by Kulkarni, A., Wright, N. M. Andrews, Forget, A. N., Ramsay, T., Mallick, R., Weberpals, J. I.

“…Purpose The objective of this study is to determine primary survival endpoints in women with recurrent and metastatic endometrial carcinoma (RMEC) treated with…”
Get full text

Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study by Weberpals, J.I., Tu, D., Squire, J.A., Amin, M.S., Islam, S., Pelletier, L.B., O'Brien, A.M., Hoskins, P.J., Eisenhauer, E.A.

“…Breast cancer 1 (BRCA1) protein inactivation in sporadic ovarian carcinoma (OC) is common and low BRCA1 expression is linked with platinum sensitivity. The…”
Get full text

Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review by Bougie, O., Weberpals, Johanne I.

“…Individuals who carry an inherited mutation in the breast cancer 1 (BRCA1) and BRCA2 genes have a significant risk of developing breast and ovarian cancer over…”
Get full text

The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy by Clancy, A.A., Spaans, J.N., Weberpals, J.I.

“…The incidence of vulvar squamous cell carcinoma (VSCC) has been on the rise since the 1990s. There has been no new treatment for advanced and recurrent disease…”
Get full text

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer by Provencher, D.M., Gallagher, C.J., Parulekar, W.R., Ledermann, J.A., Armstrong, D.K., Brundage, M., Gourley, C., Romero, I., Gonzalez-Martin, A., Feeney, M., Bessette, P., Hall, M., Weberpals, J.I., Hall, G., Lau, S.K., Gauthier, P., Fung-Kee-Fung, M., Eisenhauer, E.A., Winch, C., Tu, D., MacKay, H.J.

“…The purpose of this multistage, adaptively, designed randomized phase II study was to evaluate the role of intraperitoneal (i.p.) chemotherapy following…”
Get full text

Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3 by Lorusso, D., Coleman, R.L., Oza, A.M., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J.I., Clamp, A.R., Scambia, G., Leary, A., Holloway, R.W., Amenedo Gancedo, M., Fong, P.C., Goh, J.C., O’Malley, D.M., Banerjee, S., Goble, S., Cameron, T., Ledermann, J.A.

Get full text

First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16 by Weberpals, J.I, Amin, M.S, Chen, B.E, Tu, D, Spaans, J.N, Squire, J.A, Eisenhauer, E.A, Virk, S, Ma, D, Duciaume, M, Hoskins, P, LeBrun, D.P

“…Abstract Background Platinum resistance is a dominant cause of poor outcomes in advanced ovarian cancer (OC). A mechanism of platinum resistance is the…”
Get full text

OV21/PETROC: A Randomized Gynecologic Cancer Intergroup Phase II Study of Intraperitoneal Versus Intravenous Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery in Epithelial Ovarian Cancer by Provencher, D M, Gallagher, C J, Parulekar, W R, Ledermann, J A, Armstrong, D K, Brundage, M, Gourley, C, Romero, I, Gonzalez-Martin, A, Feeney, M, Bessette, P, Hall, M, Weberpals, J I, Hall, G, Lau, S K, Gauthier, P, Fung-Kee-Fung, M, Eisenhauer, E A, Winch, C, Tu, D, MacKay, H J

“…(Abstracted from Ann Oncol 2018;29(2):431–438)The use of neoadjuvant chemotherapy (NACT) prior to surgical debulking is increasingly used for advanced…”
Get full text

1001PEffect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment by Ledermann, J A, Oza, A M, Lorusso, D, Aghajanian, C, Oaknin, A, Dean, A, Colombo, N, Weberpals, J I, Clamp, A R, Scambia, G, Leary, A, Holloway, R W, Gancedo, M Amenedo, Fong, P C, Goh, J C, O’Malley, D M, Cameron, T, Maloney, L, Goble, S, Coleman, R L

“…Abstract Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival (PFS) vs placebo and was associated with…”
Get full text

1002PIntegrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings by Kristeleit, R S, Oza, A M, Oaknin, A, Aghajanian, C, Tinker, A V, Tredan, O, O’Malley, D M, Leary, A, Konecny, G E, Lorusso, D, Weberpals, J I, Goble, S, Maloney, L, Cameron, T, Swisher, E, McNeish, I A, Shapira-Frommer, R, Ledermann, J A, Coleman, R L

“…Abstract Background Rucaparib is approved in the European Union and the United States for use as treatment or maintenance for women with ovarian cancer. Here…”
Get full text

947PSubgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3 by Lorusso, D, Coleman, R L, Oza, A M, Aghajanian, C, Oaknin, A, Dean, A, Colombo, N, Weberpals, J I, Clamp, A R, Scambia, G, Leary, A, Holloway, R W, Amenedo Gancedo, M, Fong, P C, Goh, J C, O'Malley, D M, Banerjee, S, Goble, S, Cameron, T, Ledermann, J A

Get full text

Can tumor biomarkers predict response to neoadjuvant anthracycline/taxane chemotherapy in LABC? by Hilton, J. F., Weberpals, J. I., Lorimer, I., Nabavi, M., Kanji, F., Hopkins, S., Robertson, S., Daneshmand, M., Verma, S.

“…Abstract only…”
Get full text

Breast cancer protein expression as a prognostic marker in sporadic epithelial ovarian cancer (EOC): An NCIC CTG OV.16 correlative study by Weberpals, J. I., Tu, D., Squire, J., Islam, S., Amin, S., Pelletier, L., O'Brien, A., Hoskins, P., Eisenhauer, E. A.

“…Abstract only…”
Get full text

Investigation of HDAC inhibition targeting of BRCA1 expression as a mechanism to enhance platinum sensitivity in breast and ovarian cancer by Weberpals, J. I., O'Brien, A., Garbuio, K., Clark-Knowles, K., Dimitroulakos, J.

“…Abstract only e22017 Background: The improved outcome of Breast-Cancer 1 (BRCA1)-deficient breast and ovarian cancer may be linked to the impaired ability to…”
Get full text

The evaluation of BRCA1 and ERCC1 expression as predictors of platinum response in ovarian cancer by Weberpals, J. I., Clark-Knowles, K., O'Brien, A., Antoniouk, O., Garbuio, K., Dimitroulakos, J.

“…Abstract only…”
Get full text